Table of Contents

Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research

Related Links:

Publication date: October 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 10Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 10Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 10Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
to “Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry” [Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e283-e285]
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Tags: Corrigendum Source Type: research
ConclusionREVEAL enrollment data inform our understanding of the baseline demographics, diagnostic approach, disease characteristics, and treatment patterns of patients with PV in the United States. Longitudinal real-world data collected in this study will complement information collected during randomized controlled clinical trials.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joshua Richter, Sundar JagannathAbstractOver the last decade the survival outcomes in Multiple Myeloma (MM) have dramatically improved thanks to not only the advent of a number of novel therapies; but also, to the deepening insight regarding how to best utilize these options. Triplet-based induction regimens can yield overall response rates of up to 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options with high and durable response rates. The addition of monoclonal antibod...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur proposed nomogram based on Eastern Cooperative Oncology Group performance status, Ann Arbor stage, albumin-to-globulin ratio, and platelet count provides an individualized risk estimate of OS in patients with ENKTL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study reveals important areas of progress in cancer outcomes in Canada since the early 1990s. It also sheds light on cancers for which there has seemingly been no improvement in five-year net survival over a 20-year period. PMID: 30230521 [PubMed - in process]
Source: Health Reports - Category: International Medicine & Public Health Tags: Health Rep Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma